New Directions in Bioprocess Modeling and Control

New Directions in Bioprocess Modeling and Control

  • Gregory K. McMillan
  • Christopher Stuart
  • Rehman Fazeem
  • Zachary T. Sample
  • Timothy Schieffer
Publisher:John Wiley & SonsISBN 13: 9781643311043ISBN 10: 1643311042

Paperback & Hardcover deals ―

Amazon IndiaGOFlipkart GOSnapdealGOSapnaOnlineGOJain Book AgencyGOBooks Wagon₹4,322Book ChorGOCrosswordGODC BooksGO

e-book & Audiobook deals ―

Amazon India GOGoogle Play Books GOAudible GO

* Price may vary from time to time.

* GO = We're not able to fetch the price (please check manually visiting the website).

Know about the book -

New Directions in Bioprocess Modeling and Control is written by Gregory K. McMillan and published by John Wiley & Sons. It's available with International Standard Book Number or ISBN identification 1643311042 (ISBN 10) and 9781643311043 (ISBN 13).

New Directions in Bioprocess Modeling and Control: Maximizing Process Analytical Technology Benefits, 2nd Edition This book provides practical, comprehensive knowledge on how to use the advances in analytical measurements and basic and advanced control to improve batch profiles and endpoint consistency. The consequential integration of measurements, models, and controls into a digital twin with recently developed blocks to provide profiles and predict endpoints enables: Developing dynamic models from trend charts that are used for experiment design, diagnosing the sources of limitations and inconsistences, and developing and testing solutions 500 times real time without interfering with existing plant operation. Comprehensive views of basic process control with the possibilities of model predictive control to control and optimize batch profiles by non-intrusive development and confirmation. The ability to determine how to maximize the performance of bioreactors, which are often the bottleneck and the key to product quality and consistency, without tests or trials in the actual plant. The resulting improvements in batch cycle time and consistency can be designed, tested, quantified, and confirmed; and operators can be trained independently of actual plant operation. The benefit from the elimination of a bad batch—particularly for new biologics—is potentially worth ten or more million dollars.